The Guidance on global monitoring for diabetes prevention and control by WHO provides a comprehensive framework to support countries in tracking and managing diabetes prevention, care, and outcomes. This document outlines indicators across 4 domains: health system determinants, service delivery, ris...k factors, and outcomes/impacts. The guidance helps countries align their monitoring efforts with WHO’s global diabetes targets, Global Diabetes Compact, and relevant global NCD targets.
more
Case Manangement Training Modules
The dual epidemic of TB and Diabetes
Guía Clínica – Diabetes Mellitus tipo 1
For versions in Arabic, Russian, French, Spanish, Turkish and German go to http://www.patienten-information.de/kurzinformationen/diabetes/diabetes-und-fuesse
Guidelines and Consensus for the Diagnosis, Management and Prevention of Type 2 Diabetes Mellitus in Indonesia
This manual aims to provide an overview of this subject to health care professionals, paramedics and other voluntary services involved in health care promotion
WHO Package of Essential NCD Interventions (PEN)
Accessed March 18,2019
Updated 24 March 2020 (24 Maart 2020)
Tenho hipertensão ou diabetes, como me cuidar na pandemia?
Em tempos da covid-19, pessoas com doenças crônicas precisam reforçar o autocuidado
Patients with diabetes are at increased risk of developing cardiovascular disease (CVD) with its manifestations of coronary artery disease (CAD), heart failure (HF), atrial fibrillation (AF), and stroke, as well as aortic and peripheral artery diseases. In addition, diabetes is a major risk factor f...or developing chronic kidney disease (CKD), which in itself is associated with developing CVD. The combination of diabetes with these cardio-renal comorbidities enhances the risk not only for cardiovascular (CV) events but also for CV and all-cause mortality. The current European Society of Cardiology (ESC) Guidelines on the management of cardiovascular disease in patients with diabetes are designed to guide prevention and management of the manifestations of CVD in patients with diabetes based on data published until end of January 2023. Over the last decade, the results of various large cardiovascular outcome trials (CVOTs) in patients with diabetes at high CV risk with novel glucose- lowering agents, such as sodium–glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists (RAs), but also novel non-steroidal mineralocorticoid receptor antagonists (MRAs), such as finerenone have substantially expanded available therapeutic op-
tions, leading to numerous evidence-based recommendations for the management of this patient population.
more